SANDOSTATIN® LAR Depot (octreotide acetate) for Acromegaly

Acromegaly

Sandostatin^® LAR Depot (octreotide acetate) for injectable suspension for long-term maintenance of acromegaly.¹

Efficacy

Help patients reach normal GH^† and IGF-1 levels¹

HIGHLIGHTS OF IMPORTANT SAFETY INFORMATION

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of cholelithiasis (gallstones) resulting in complications; glucose metabolism; thyroid and cardiac function; and nutritional absorption (periodic monitoring is recommended). Cardiac function: use with caution in at-risk patients.

Drug Interactions: The following drugs require monitoring and possible dose adjustment when used with Sandostatin LAR Depot: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

For lutetium Lu 177 dotatate injection: Discontinue Sandostatin LAR Depot at least 4 weeks prior to each lutetium Lu 177 dotatate dose

Adverse Reactions: The most common adverse reactions occurring in ≥20% of patients are diarrhea, cholelithiasis, abdominal pain, and flatulence

Please see additional Important Safety Information below.

STUDY DESIGN

In 2 clinical trials, patients were entered who had, in most cases, achieved a GH level <5 ng/mL on Sandostatin^® (octreotide acetate) Immediate-Release Injection given in doses of 100 mcg or 200 mcg 3 times daily. Most patients were switched to 20 mg or 30 mg doses of Sandostatin LAR Depot given once every 4 weeks for up to 27 to 28 injections. A few patients received doses of 10 mg and a few required doses of 40 mg.

A third trial was a 12-month study in patients who had a GH level <10 ng/mL after treatment with Sandostatin Immediate-Release Injection (most had levels <5 ng/mL). The starting dose of Sandostatin LAR Depot was 20 mg every 4 weeks for 3 doses. Thereafter, patients received 10 mg, 20 mg, or 30 mg every 4 weeks, depending on the degree of GH suppression.¹

GH, growth hormone; IGF-1, insulin-like growth factor 1; LAR, long-acting release.

*Includes Sandostatin^® (octreotide acetate) Immediate-Release Injection and Sandostatin^® LAR Depot (octreotide acetate) for injectable suspension for all approved indications.

^†Safe GH levels considered <2.5 ng/mL.^1,3,4

Patient Resources

The right support at the right time

The single source for patient and caregiver support
Financial assistance option to help patients get access to the treatment(s) they need
Personalized 1-on-1 support through unique programs designed to work with patients when they’re needed most

To learn more about what the Novartis Oncology Patient Support Program can offer your patients, call 1-800-282-7630 or visit Novartis Patient Support.

Mobile Administration Program (MAP)

This program offers administration of Sandostatin^® LAR Depot (octreotide acetate) for injectable suspension by a registered nurse at a time and place convenient for your eligible patients so they continue to receive the correct prescribed dose at the right time.^*

Trained MAP nurses will prepare and administer the medication^†
Receive a report after each patient administration
Administration is available on nights and weekends, and when patients are traveling within the continental United States
Patients can receive their treatment at their home or workplace, or at another convenient location of their choice

The MAP is an additional benefit for all appropriate and eligible patients with acromegaly for whom Sandostatin LAR Depot has been prescribed.

Patients must be recommended by their physician
Residents of all states except Massachusetts, Michigan, Minnesota, and Rhode Island can participate
The program is available to patients covered by most commercial plans (HMO, PPO, etc)
Patients with government-provided medical insurance (eg, Medicare Part B and D, or Medicaid) are not eligible

Your office can confirm patient eligibility easily by calling 1-877-503-3377 and speaking with a representative. You can also print the enrollment form by clicking here.

Advantages of the MAP

Because the program provides specially trained registered nurses, you can feel confident about the following:

No guesswork. You know that your patient will receive the right dose, at the right time, using the right technique
Feedback from registered nurses. The nurse will submit a detailed report to you after each visit. You will know when the patient receives his/her treatment at the prescribed dose
Your patients can receive injections when it is convenient for their schedule. Nurses are available outside traditional office hours, including weekends and evenings, even when patients are traveling within the continental United States
Time saved for your patient. Your patient won't need to make long trips to the treatment center
Nurse handles all needle disposals. The program nurse handles disposal of all equipment

The MAP program is not intended to replace the care provided by a patient's health care team

How MAP works

As the prescribing physician, you evaluate your patients on a case-by-case basis and decide who is appropriate for the program
Your office submits the patient's information to the company that administers the program, in 1 of 2 ways:

– By calling 1-877-503-3377 or

– By completing and sending in the enrollment form

Patient eligibility is verified according to your patient's insurance plan
Your patient receives a call to discuss his or her preferences and schedule the next injection.^‡ Patients must receive their first dose of Sandostatin LAR Depot in your office
A specially trained treatment nurse visits your patient's home and:

– Administers the injection

– Schedules the next appointment and follows up with a reminder

– Sends a report to you, the prescribing physician, to update you on the patient’s status

*The program does not replace your care or the authority of the prescribing physician. Patients still keep their regularly scheduled physician checkups. First dose must be administered by prescribing physician.
^†Limitations apply. Available only for patients with private insurance. Program not available for patients with Medicare, Medicaid, or any other federal or state program. Program not available for residents of Massachusetts, Michigan, or Rhode Island.
^‡Patient is responsible for acquiring his or her own medication.